Hwang Sang-youn is a trailblazer who has not hesitated to change his life s path during the last three decades of his career. His diverse work experiences as a stellar engineer, stock analyst, CFO and CEO led the 52-year to establish a private equity company of his own, Aimbridge LLC, earlier this year.
Heart Failure Clinical Trial Pipeline Insights | 75+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space | medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.
Chong Kun Dang (CKD) is accelerating the development of new drugs by significantly expanding investments in research and development, the pharmaceutical company said Sunday. During the first five months of this year, CKD spent 181.4 billion won ($141.7 million) or 12.2 percent of its annual sales in 2022 to expand the scope of new drug development to advanced biopharmaceuticals and antibody drug conjugates (ADC) such as gene and cell therapies. The pharmaceutical company is expected to focus on first-in-class drugs and responding to unmet needs in the medical market.
EconoTimes is a fast growing non-partisan source of news and intelligence on global economy and financial markets, providing timely, relevant, and critical insights for market professionals and those who want to make informed investment decisions.
Lonza Group AG / Key word(s): Acquisition/Mergers & Acquisitions Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering 01.06.2023 / 07:00 CET/CEST Lonza to acquire